O-RADS US Risk Stratification Model for Adnexal Lesions
The O-RADS (Ovarian-Adnexal Reporting and Data System) US model is a standardized 5-category risk stratification system developed by the American College of Radiology that assigns adnexal lesions to categories 0-5 based on ultrasound features, with each category corresponding to specific malignancy risk percentages and management recommendations 1.
Risk Categories and Malignancy Rates
The O-RADS system stratifies lesions into the following categories:
O-RADS 0: Incomplete Evaluation
- Requires repeat ultrasound or alternate imaging (such as MRI)
- Used when initial evaluation is technically inadequate 1
O-RADS 1: Normal Ovary (0% malignancy risk)
- Premenopausal women only
- Includes physiologic findings:
- Follicles: simple cysts <3 cm
- Corpus luteum: thick-walled cyst <3 cm with crenulated inner margin, internal echoes, and peripheral flow 1
- Management: No follow-up needed
O-RADS 2: Almost Certainly Benign (<1% malignancy risk)
Key features include:
- Simple cysts:
- 3-5 cm: no follow-up in premenopausal; 8-12 week follow-up in postmenopausal
- 5-10 cm: annual follow-up in premenopausal; specialist referral or MRI in postmenopausal
- Classic benign lesions <10 cm:
- Typical hemorrhagic cysts (reticular pattern or retracting clot)
- Typical dermoid cysts (hyperechoic with shadowing, lines/dots pattern)
- Typical endometriomas (ground glass/homogeneous low-level echoes)
- Paraovarian cysts, peritoneal inclusion cysts, hydrosalpinx
- Non-simple unilocular cysts with smooth inner margins <10 cm 1
Management: Generally no follow-up or conservative surveillance; US specialist or MRI if concerning features develop
O-RADS 3: Low Risk (1% to <10% malignancy risk)
Includes:
- Unilocular cysts ≥10 cm (simple or non-simple)
- Classic benign lesions ≥10 cm (dermoid, endometrioma, hemorrhagic cyst)
- Unilocular cysts with irregular inner wall <3 mm height
- Multilocular cysts <10 cm with smooth inner wall and color score 1-3
- Avascular solid lesions with smooth contour 1
Management: Gynecologist evaluation
O-RADS 4: Intermediate Risk (10% to <50% malignancy risk)
Features include:
- Multilocular cysts (any size) with smooth inner wall and color score 4
- Lesions with irregular inner wall and/or irregular septation (any color score)
- Unilocular cysts with 0-3 papillary projections (any color score)
- Multilocular cysts ≥10 cm or with solid components 1
Management: US specialist or MRI for further characterization; gynecologist with gynecologic oncologist consultation
Clinical Pearl: Recent research suggests Category 4 can be further subdivided into 4a (low-risk) and 4b (high-risk) based on locule count (>10 locules indicates higher risk) and color score, which may reduce unnecessary surgeries by approximately 18% 2.
O-RADS 5: High Risk (≥50% malignancy risk)
High-risk features:
- Unilocular cysts with ≥4 papillary projections (any color score)
- Multilocular cysts with solid component and color score 3-4
- Solid smooth lesions with color score 4
- Solid irregular lesions (any color score)
- Ascites and/or peritoneal nodules (except when associated with O-RADS 1-2 lesions, where other etiologies must be considered) 1
Management: Gynecologic oncologist management
Key Algorithmic Features
Color Score Integration
The color score (vascularity assessment) becomes critical starting at O-RADS 3:
- Score 1: No flow
- Score 2: Minimal flow
- Score 3: Moderate flow
- Score 4: Intense flow 1
Size Thresholds
- 10 cm cutoff: Critical threshold where malignancy risk increases significantly, even for otherwise benign-appearing lesions
- 3 cm cutoff: Distinguishes physiologic findings from true lesions 1
Menopausal Status Matters
Management differs significantly between premenopausal and postmenopausal women, with postmenopausal patients requiring more aggressive follow-up or specialist referral for the same lesion characteristics 1.
Clinical Validation and Performance
The O-RADS US system has demonstrated high sensitivity for malignancy detection with good specificity and strong interobserver agreement 3. Validation studies show the system performs comparably in pediatric populations (ages ≤17 years) with an AUC of 0.989, supporting its broad applicability 4.
Common Pitfalls to Avoid
- Don't overlook the 10 cm threshold: Even classic benign lesions ≥10 cm move to O-RADS 3 due to increased malignancy risk
- Color score is mandatory for O-RADS 3-5: Failure to assess vascularity leads to inaccurate categorization
- Papillary projections must be ≥3 mm in height: Smaller irregularities are classified differently
- Ascites with benign lesions: Always consider alternative etiologies (cirrhosis, heart failure, etc.) before assuming malignancy 1
Integration with Other Models
The O-RADS system can be complemented by the ADNEX model (Assessment of Different Neoplasias in the Adnexa), which uses six ultrasound features plus CA-125 and patient age to calculate precise malignancy probabilities. The IOTA two-step strategy (Simple Rules followed by expert assessment) shows comparable or slightly superior performance (AUC 0.992) but requires specialized expertise 4.
O-RADS MRI serves as a problem-solving tool for technically limited cases or when additional characterization is needed, with specificities approaching 90-95% 3.